Back

Novo Nordisk shares fall 4.8% after Cagrisema trial results

Verifying
  • Novo Nordisk released topline results from two Phase 3 Cagrisema trials.
  • 4.8%: Novo Nordisk shares fell to $41.15 in pre-market trading.
  • Telix Pharmaceuticals signed an agreement to lead a merger with ITM Isotope Technologies Munich SE.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.